Guthán: 01 8647100



Primary Care Reimbursement Service Exit 5, M50, North Road, Finglas, Dublin 11, D11 XKF3

Tel: 01-8647100

Maurice Quinlivan, T.D. Dáil Éireann, Leinster House, Kildare Street, Dublin 2.

1st November 2022

PQ: 51953/22

To ask the Minister for Health the status of the 2021 application to HSE to have the NovoPen 6 and the NovoPen echo plus smart insulin pens included for reimbursement on the long-term illness scheme; the reason that this particular application still has not concluded over 12 months after the application was submitted; and if he will make a statement on the matter. -Maurice Quinlivan

Dear Deputy Quinlivan,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 51953/22), which you submitted to the Minister for Health for response.

Consumable products classified as non-drug (medical devices) can be submitted for the following categories;

- Clinical Nutritional Products
- Urinary Products
- Ostomy Products
- Wound Management Products
- Personal diagnostic, monitoring and delivery devices (for diabetes)

Reimbursement guidelines for these categories are found at https://www.hse.ie/eng/about/who/cpu/non-drug-reimbursement-applications/.

NovoPen 6 and NovoPen Echo Plus smart pens are not reimbursable under Community Drug Schemes, including the Long Tern Illness Scheme. These smart pens are pieces of equipment which last between 4-5 years. PCRS deal with consumable products that are dispensed on a monthly basis and do not reimburse equipment.

Therefore, the pricing and reimbursement application submitted to the PCRS in 2021 by the Marketing Authorisation Holder is for a product (equipment) that does not fall under the non-drug reimbursement application process. This application process is available for

consumable products as published on the HSE website at https://www.hse.ie/eng/about/who/cpu/non-drug-reimbursement-applications/non-drug-application-flow-chart.pdf.

Following review and consideration of the application submitted, the Marketing Authorisation Holder was informed that the product did not satisfy the criteria for reimbursement of non-drug items under Community Drug Schemes at the beginning of September 2022.

Yours sincerely,

Suzanne Doyle

ryanne Doj 6

Primary Care Eligibility & Reimbursement Service